Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) PT lowered to €23.00 at JPMorgan Chase & Co.

0

Fresenius Medical Care AG & Co. KGaA (New York Stock Exchange: FMSGet a rating) saw its price target revised downwards by analysts to JPMorgan Chase & Co. from €51.00 ($52.58) to €23.00 ($23.71) in a report released on Monday, Fly reports.

Other stock analysts have also published research reports on the company. UBS Group downgraded Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “neutral” rating in a Friday, July 29 research note. DZ Bank downgraded Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “hold” rating in a Friday, July 29 research note. Truist Financial cut its price target on Fresenius Medical Care AG & Co. KGaA from $34.00 to $27.00 and set a “hold” rating on the stock in a Wednesday, June 22 research note. StockNews.com downgraded Fresenius Medical Care AG & Co. KGaA from a “strong buy” rating to a “buy” rating in a Friday, July 15 research note. Finally, Jefferies Financial Group upgraded Fresenius Medical Care AG & Co. KGaA from an “underperforming” rating to a “buy” rating and raised its price target for the stock from $30.30 to 33.70. $ in a research note from Monday, June 27. One analyst rated the stock with a sell rating, eight issued a hold rating and four issued the company a buy rating. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $49.01.

Fresenius Medical Care AG & Co. KGaA share performance

Shares of Action Fresenius Medical Care AG & Co. KGaA opened at $18.31 on Monday. The company has a market capitalization of $10.73 billion, a P/E ratio of 11.66, a P/E/G ratio of 0.85 and a beta of 1.03. The company has a current ratio of 1.26, a quick ratio of 0.93 and a debt ratio of 0.51. Fresenius Medical Care AG & Co. KGaA has a 12-month low of $18.16 and a 12-month high of $40.85. The stock’s fifty-day moving average price is $25.07 and its 200-day moving average price is $29.91.

Fresenius Medical Care AG & Co. KGaA (New York Stock Exchange: FMSGet a rating) last reported quarterly results on Wednesday, May 4. The company reported EPS of $0.38 for the quarter, beating the consensus estimate of $0.30 by $0.08. The company posted revenue of $5.10 billion for the quarter, versus analyst estimates of $4.97 billion. Fresenius Medical Care AG & Co. KGaA achieved a return on equity of 6.72% and a net margin of 4.42%. On average, equity research analysts expect Fresenius Medical Care AG & Co. KGaA to post earnings per share of 1.79 for the current fiscal year.

Institutional entries and exits

Major investors have recently been buying and selling stocks. Tcwp LLC acquired a new position in Fresenius Medical Care AG & Co. KGaA in the first quarter worth approximately $44,000. SRS Capital Advisors Inc. increased its position in shares of Fresenius Medical Care AG & Co. KGaA by 36.0% in the first quarter. SRS Capital Advisors Inc. now owns 1,545 shares of the company valued at $52,000 after buying 409 additional shares in the last quarter. Creative Financial Designs Inc. ADV purchased a new stake in shares of Fresenius Medical Care AG & Co. KGaA in the first quarter, valued at approximately $67,000. GHP Investment Advisors Inc. purchased a new equity stake in Fresenius Medical Care AG & Co. KGaA in the first quarter, valued at approximately $72,000. Finally, Signaturefd LLC increased its position in shares of Fresenius Medical Care AG & Co. KGaA by 26.4% in the first quarter. Signaturefd LLC now owns 2,190 shares of the company valued at $74,000 after purchasing an additional 458 shares in the last quarter. 4.73% of the shares are held by institutional investors and hedge funds.

Fresenius Medical Care AG & Co. KGaA Company Profile

(Get a rating)

Fresenius Medical Care AG & Co KGaA provides dialysis care and related dialysis care services in Germany, North America and abroad. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; equipment, training and patient support services including clinical monitoring, assisting with follow-up and arranging delivery of supplies to the patient’s home; and contracted dialysis services with hospitals in the United States for hospitalized patients with end-stage renal disease (ESRD) and for patients with acute renal failure.

Further reading

The Fly logo

Analyst Recommendations for Fresenius Medical Care AG & Co. KGaA (NYSE: FMS)



Get news and reviews for Fresenius Medical Care AG & Co. KGaA Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com’s free daily email newsletter .

Share.

Comments are closed.